Proteinase-activated Receptor 2 Expression in Breast Cancer and Its Role in Breast Cancer Cell Migration

Overview

Journal Oncogene

Specialties Molecular Biology
Oncology

Date 2009 Jun 23

PMID 19543320

Citations 42

Authors

S Su

Y Li

Y Luo

Y Sheng

Y Su

R N Padia

Z K Pan

Z Dong

S Huang

Affiliations

Soon will be listed here.

Abstract

Proteinase-activated receptor 2 (PAR2) is a G protein-coupled receptor that is activated by trypsin-like proteinases. PAR2 is detected in breast tumor specimens; however, it is not clear how PAR2 level in breast cancer cell/tissues compares with normal cell/tissues. Here, we show the elevation of PAR2 protein level in 76 of 105 breast tumor specimens but only 5 of 24 normal breast tissues. PAR2 level is also higher in breast cancer cell lines than that in normal breast cells and non-cancerous breast cell lines. To determine the role of PAR2 in breast carcinogenesis, we examined the effect of PAR2 agonists on cell proliferation and migration. Our studies show that PAR2 agonists (PAR2-activating peptide and trypsin) are neither potent growth enhancers nor chemoattractants to breast cancer cells. Instead, PAR2 agonists induce significant chemokinesis. PAR2-mediated chemokinesis is G(alphai)-dependent, and inhibiting Src kinase activity or silencing c-Src expression blocks PAR2-mediated chemokinesis. These results suggest that c-Src works downstream of G(alphai) to mediate this PAR2 agonist-induced event. To characterize c-Src effector, we reveal that PAR2 agonists activate JNKs in a Src-dependent manner and that JNK activity is essential for PAR2-mediated chemokinesis. Moreover, PAR2 agonist stimulation leads to paxillin Ser(178) phosphorylation and paxillin(S178A) mutant inhibits PAR2-mediated chemokinesis. In conclusion, our studies show that PAR2 agonists facilitate breast cancer cell chemokinesis through the G(alphai)-c-Src-JNK-paxillin signaling pathway.

Citing Articles

The role of non-coding RNAs in extracellular vesicles in breast cancer and their diagnostic implications.

Samuels M, Jones W, Towler B, Turner C, Robinson S, Giamas G Oncogene. 2023; 42(41):3017-3034.

PMID: 37670020 PMC: 10555829. DOI: 10.1038/s41388-023-02827-y.

Shear Stress Drives the Cleavage Activation of Protease-Activated Receptor 2 by PRSS3/Mesotrypsin to Promote Invasion and Metastasis of Circulating Lung Cancer Cells.

Zhou M, Li K, Luo K Adv Sci (Weinh). 2023; 10(25):e2301059.

PMID: 37395651 PMC: 10477893. DOI: 10.1002/advs.202301059.

Piezo1 activation attenuates thrombin-induced blebbing in breast cancer cells.

OCallaghan P, Engberg A, Eriksson O, Fatsis-Kavalopoulos N, Stelzl C, Sanchez G J Cell Sci. 2022; 135(7).

PMID: 35274124 PMC: 9016622. DOI: 10.1242/jcs.258809.

An Insight into GPCR and G-Proteins as Cancer Drivers.

Chaudhary P, Kim S Cells. 2021; 10(12).

PMID: 34943797 PMC: 8699078. DOI: 10.3390/cells10123288.

Downregulation of matriptase suppresses the PAR‑2/PLCγ2/PKC‑mediated invasion and migration abilities of MCF‑7 breast cancer cells.

Kim J, Park J, Noh E, Song H, Kang S, Jung S Oncol Rep. 2021; 46(6).

PMID: 34608498 PMC: 8524316. DOI: 10.3892/or.2021.8198.

References

Huang Z, Yan D, Ge B . JNK regulates cell migration through promotion of tyrosine phosphorylation of paxillin. Cell Signal. 2008; 20(11):2002-12. DOI: 10.1016/j.cellsig.2008.07.014. View

Xie W, Herschman H . v-src induces prostaglandin synthase 2 gene expression by activation of the c-Jun N-terminal kinase and the c-Jun transcription factor. J Biol Chem. 1995; 270(46):27622-8. DOI: 10.1074/jbc.270.46.27622. View

Versteeg H, Schaffner F, Kerver M, Petersen H, Ahamed J, Felding-Habermann B . Inhibition of tissue factor signaling suppresses tumor growth. Blood. 2007; 111(1):190-9. PMC: 2200804. DOI: 10.1182/blood-2007-07-101048. View

Ching Y, Leong V, Lee M, Xu H, Jin D, Ng I . P21-activated protein kinase is overexpressed in hepatocellular carcinoma and enhances cancer metastasis involving c-Jun NH2-terminal kinase activation and paxillin phosphorylation. Cancer Res. 2007; 67(8):3601-8. DOI: 10.1158/0008-5472.CAN-06-3994. View

Nishibori M, Mori S, Takahashi H . Physiology and pathophysiology of proteinase-activated receptors (PARs): PAR-2-mediated proliferation of colon cancer cell. J Pharmacol Sci. 2005; 97(1):25-30. DOI: 10.1254/jphs.fmj04005x5. View

Su S, Motoo Y, Iovanna J, Xie M, Mouri H, Ohtsubo K . Expression of p8 in human pancreatic cancer. Clin Cancer Res. 2001; 7(2):309-13. View

Fanger G, Johnson N, Johnson G . MEK kinases are regulated by EGF and selectively interact with Rac/Cdc42. EMBO J. 1997; 16(16):4961-72. PMC: 1170131. DOI: 10.1093/emboj/16.16.4961. View

Morris D, Ding Y, Ricks T, Gullapalli A, Wolfe B, Trejo J . Protease-activated receptor-2 is essential for factor VIIa and Xa-induced signaling, migration, and invasion of breast cancer cells. Cancer Res. 2006; 66(1):307-14. DOI: 10.1158/0008-5472.CAN-05-1735. View

Trejo J . Protease-activated receptors: new concepts in regulation of G protein-coupled receptor signaling and trafficking. J Pharmacol Exp Ther. 2003; 307(2):437-42. DOI: 10.1124/jpet.103.052100. View

10.

Yada K, Shibata K, Matsumoto T, Ohta M, Yokoyama S, Kitano S . Protease-activated receptor-2 regulates cell proliferation and enhances cyclooxygenase-2 mRNA expression in human pancreatic cancer cells. J Surg Oncol. 2005; 89(2):79-85. DOI: 10.1002/jso.20197. View

11.

Black P, Mize G, Karlin P, Greenberg D, Hawley S, True L . Overexpression of protease-activated receptors-1,-2, and-4 (PAR-1, -2, and -4) in prostate cancer. Prostate. 2007; 67(7):743-56. DOI: 10.1002/pros.20503. View

12.

Darmoul D, Gratio V, Devaud H, Laburthe M . Protease-activated receptor 2 in colon cancer: trypsin-induced MAPK phosphorylation and cell proliferation are mediated by epidermal growth factor receptor transactivation. J Biol Chem. 2004; 279(20):20927-34. DOI: 10.1074/jbc.M401430200. View

13.

Wang H, Wen S, Bunnett N, Leduc R, Hollenberg M, MacNaughton W . Proteinase-activated receptor-2 induces cyclooxygenase-2 expression through beta-catenin and cyclic AMP-response element-binding protein. J Biol Chem. 2007; 283(2):809-15. DOI: 10.1074/jbc.M703021200. View

14.

Sanchez-Hernandez P, Ramirez-Duenas M, Albarran-Somoza B, Garcia-Iglesias T, Del Toro-Arreola A, Franco-Topete R . Protease-activated receptor-2 (PAR-2) in cervical cancer proliferation. Gynecol Oncol. 2007; 108(1):19-26. DOI: 10.1016/j.ygyno.2007.08.083. View

15.

Matej R, Mandakova P, Netikova I, Pouckova P, Olejar T . Proteinase-activated receptor-2 expression in breast cancer and the role of trypsin on growth and metabolism of breast cancer cell line MDA MB-231. Physiol Res. 2006; 56(4):475-484. DOI: 10.33549/physiolres.930959. View

16.

Caruso R, Pallone F, Fina D, Gioia V, Peluso I, Caprioli F . Protease-activated receptor-2 activation in gastric cancer cells promotes epidermal growth factor receptor trans-activation and proliferation. Am J Pathol. 2006; 169(1):268-78. PMC: 1698759. DOI: 10.2353/ajpath.2006.050841. View

17.

Abdulrahman M, Maina E, Morris M, Zatyka M, Raval R, Banks R . Identification of novel VHL targets that are associated with the development of renal cell carcinoma. Oncogene. 2006; 26(11):1661-72. DOI: 10.1038/sj.onc.1209932. View

18.

Massi D, Naldini A, Ardinghi C, Carraro F, Franchi A, Paglierani M . Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma. Hum Pathol. 2005; 36(6):676-85. DOI: 10.1016/j.humpath.2005.04.008. View

19.

Shi X, Gangadharan B, Brass L, Ruf W, Mueller B . Protease-activated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis. Mol Cancer Res. 2004; 2(7):395-402. View

20.

Dandrea M, Derian C, Santulli R, Andrade-Gordon P . Differential expression of protease-activated receptors-1 and -2 in stromal fibroblasts of normal, benign, and malignant human tissues. Am J Pathol. 2001; 158(6):2031-41. PMC: 1891970. DOI: 10.1016/S0002-9440(10)64675-5. View